LENZ Therapeutics Inc
LENZ
Company Profile
Business description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Contact
201 Lomas Santa Fe Drive
Suite 300
Solana BeachCA92075
USAT: +1 858 925-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
152
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 16.10 | -0.18% |
| CAC 40 | 8,272.44 | 58.60 | -0.70% |
| DAX 40 | 24,394.72 | 23.08 | -0.09% |
| Dow JONES (US) | 49,662.66 | 220.10 | 0.45% |
| FTSE 100 | 10,530.67 | 78.41 | -0.74% |
| HKSE | 26,487.48 | 126.41 | 0.48% |
| NASDAQ | 24,498.86 | 94.47 | 0.39% |
| Nikkei 225 | 59,349.17 | 524.28 | 0.89% |
| NZX 50 Index | 12,932.33 | 16.88 | 0.13% |
| S&P 500 | 7,126.28 | 17.14 | 0.24% |
| S&P/ASX 200 | 8,949.40 | 20.10 | -0.22% |
| SSE Composite Index | 4,085.08 | 2.95 | 0.07% |